[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep-disordered-breathing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep-disordered-breathing":92},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,46,78,104,138,182,213,248,282,310,337,359,384,413,437,460],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":28,"conditions":29,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100484569","phase-1-sleep-disordered-breathing-with-opioid-use-100484569",false,"NCT05589753","Sleep Disordered Breathing With Opioid Use","Targeting Chemoreceptor Control of Breathing During Sleep to Mitigate Opioid-Associated Sleep Disordered Breathing","SDB","Inclusion Criteria:\n\n* Veterans, age 18-89 years\n* Veterans with prescription opioids\n\nExclusion Criteria:\n\n* Patients with BMI\\>40kg\u002Fm2 will be excluded to avoid the effects of morbid obesity on pulmonary mechanics and ventilatory control\n* Patients with history of unresolved\u002Funtreated cardiac disease, including recent myocardial infarction, recent bypass surgery, untreated atrial and ventricular tachy-bradycardias\n* Congestive heart failure with Cheyne-Stokes respiration (CSR)\n* Current unstable angina\n* Recent stroke\n* Untreated schizophrenia\n* Untreated hypothyroidism\n* Unresolved seizure disorder\n* Severe respiratory, neurological, liver and renal diseases\n* Unstable psychiatric disorders\u002Funtreated PTSD\n* Traumatic brain injury\n* Pregnant women\n* Significant sleep disorder such as narcolepsy, parasomnias disorder\n* Failure to give informed consent\n* Patients on tramadol and suboxone\u002Fbuprenorphine",true,"ALL","18 Years","89 Years",{"count":22,"type":23},150,"ESTIMATED","INTERVENTIONAL",[26,27],"PHASE1","PHASE2","There is an increased risk for sleep disordered breathing (SDB), sleep-related hypoventilation and irregular breathing in individuals on chronic prescription opioid medications. Almost 30% of a veteran sleep clinic population had opioid-associated central sleep apnea (CSA). The proposal aims to identity whether oxygen and acetazolamide can be effective in reducing unstable breathing and eliminating sleep apnea in chronic opioid use via different mechanisms. We will study additional clinical parameters like quality of life, sleep and pain in patients with and without opioid use. This proposal will enhance the investigators' understanding of the pathways that contribute to the development of sleep apnea with opioid use. The investigators expect that the results obtained from this study will positively impact the health of Veterans by identifying new treatment modalities for sleep apnea.",[30,31,32],"Sleep Apnea","Opioid Use","Sleep Disordered Breathing","RECRUITING","2026-06-29",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":37},"2019-05-02",{"date":41,"type":23},"2027-03-31",{"name":43,"class":44},"VA Office of Research and Development","FED",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100639471","phase-1-combination-upper-airway-electrical-and-pharmacological-stimulation-for-obstructive-sleep-apnea-100639471","NCT07577661","Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea","Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea: A Randomized-Controlled Trial.","Inclusion Criteria for Enrolment:\n\n* Ages 18 - 79 years\n* Diagnosed OSA\n* Implantation of a hypoglossal nerve stimulation device (HGNS, Inspire Medical) or scheduled for implantation (implantation required for randomization)\n* Willingness to withhold HGNS while testing therapies (up to 6 weeks with HGNS off \\[with\u002Fwithout pharmacotherapy\\] to assess benefits of HGNS therapy).\n\nExclusion Criteria:\n\n* Any uncontrolled medical condition\n* Current use of the medications under investigation.\n* Issues relating to short-term withdrawal of HGNS therapy\n\n  * Excluded: Occupational driving (truck drivers, fork-lift operation, taxi\u002Fuber drivers)\n  * Excluded: History of traffic accidents attributable to sleepiness or fatigue (\\\u003C2 years).\n* Use of SNRIs\u002FSSRIs or anticholinergic medications during the study.\n* Conditions likely to affect obstructive sleep apnea physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition.\n* Respiratory disorders other than sleep disordered breathing:\n\nchronic hypoventilation\u002Fhypoxemia (awake SaO2 \\\u003C 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions.\n\n* Other sleep disorders: narcolepsy, parasomnias. Insomnia\n* Contraindications for atomoxetine and oxybutynin, including:\n\n  * hypersensitivity to atomoxetine or oxybutynin (angioedema or urticaria)\n  * pheochromocytoma\n  * use of monoamine oxidase inhibitors\n  * diagnosed benign prostatic hypertrophy, urinary retention\n  * suspected benign prostatic hypertrophy \u002F urinary retention based on a positive answer to either of the following questions:\n\n    1. \"During the last month, when urinating, have you had the sensation of not emptying your bladder completely more often than 1 out of 5 times?\"\n    2. \"During the last month, have you had a weak urinary stream more often than 1 out of 5 times?\n  * known untreated narrow angle glaucoma\n  * known bipolar disorder, mania, psychosis\n  * known history of major depressive disorder (age\\\u003C24).\n  * known history of attempted suicide or suicidal ideation within one year prior to screening\n  * known clinically significant constipation, gastric retention\n  * known pre-existing seizure disorders\n  * known clinically-significant kidney disorders (eGFR\\\u003C60 ml\u002Fmin\u002F1.73m2)\n  * known clinically-significant liver disorders\n  * known clinically-significant cardiovascular conditions\n  * moderate-to-severe hypertension (SBP\\>160 mmHg or DBP\\>100 mmHg measured at baseline; average of evening and morning measures)\n  * known cardiomyopathy (LVEF\\\u003C50%) or heart failure\n  * known advanced atherosclerosis\n  * recent cerebrovascular events (within 2 years)\n  * recent history of cardiac arrhythmias e.g., atrial fibrillation, QT prolongation (within 2 years)\n  * other serious cardiac conditions that would raise the consequences of an increase in blood pressure or heart rate\n  * myasthenia gravis\n  * pregnancy\u002Fbreast-feeding","79 Years",{"count":55,"type":23},24,[26,27],"Obstructive sleep apnea (OSA) is a common condition in which the airway repeatedly collapses during sleep, leading to poor sleep quality and reduced oxygen levels. Hypoglossal nerve stimulation (HGNS) is an approved treatment that uses a small implanted device to stimulate the genioglossus muscle and keep the airway open. However, some patients continue to have OSA despite using HGNS. Atomoxetine and oxybutynin, \"AtoOxy\", is a promising pharmacologcal therapy under investigation that has been shown to activate pharyngeal muscles-in particular non-genioglossus muscles--but appears more efficacious in some patients than others.\n\nThis study will test whether the combination of AtoOxy and HGNS can further improve breathing during sleep compared to either monotherapy alone. Participants with OSA and an HGNS device will be randomized to receive, in random order: HGNS+AtoOxy, HGNS alone (plus placebo), AtoOxy alone (HGNS device off), and placebo (HGNS device off), in a cross-over trial.\n\nThe main goal is to determine whether the combined treatment reduces the number of breathing events during sleep; the primary outcome test will compare HGNS+AtoOxy versus HGNS alone. The effect of each intervention versus placebo will also be presented.\n\nThe study will also examine how individual patient characteristics influence response to treatment.",[59,60],"Obstructive Sleep Apnea","Sleep-disordered Breathing",[62,63,64,65,66],"Obstructive sleep apnea","Pharmacotherapy","Hypoglossal nerve stimulation","Oxybutynin","Atomoxetine","NOT_YET_RECRUITING","2026-05-04",{"date":70,"type":37},"2026-05-11",{"date":72,"type":23},"2026-06-01",{"date":74,"type":23},"2027-12-01",{"name":76,"class":77},"Brigham and Women's Hospital","OTHER",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":18,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":24,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":102,"locationsCount":45},"100506949","home-initiation-of-noninvasive-positive-pressure-ventilation-in-children-with-medical-complexity-100506949","NCT05881031","Home Initiation of Noninvasive Positive Pressure Ventilation in Children With Medical Complexity","Single Site Feasibility and Safety Study of Home Initiation of Noninvasive Positive Pressure Ventilation in Children With Medical Complexity","Inclusion Criteria:\n\n1. Age 5-17 years old\n2. Newly prescribed NiPPV\n3. Tolerated awake NiPPV trial\n4. Provides informed consent\n\nExclusion Criteria:\n\n1. Cardiac disease at risk of hemodynamic instability with NiPPV initiation (eg cardiac dysfunction (ejection fraction \\\u003C45%), pulmonary hypertension (mean pulmonary artery pressure ≥ 20 mmHg on right heart catheterization or suggestive echocardiogram findings in the opinion of a pediatric cardiologist), or single ventricle)\n2. At high risk of complications with NiPPV in the opinion of the child's physician (eg pneumothorax and aspiration risk)\n3. Severe sleep disordered breathing with peak CO2 ≥ 60mmHg or apnea-hypopnea index (AHI)≥ 30\u002Fhr (AHI measures the number of respiratory events per hour)\n4. Participation in concurrent research study that may affect NiPPV adherence (proposed primary outcome of full study)\n5. Exclusion of study participants if the caregiver or participant is not English speaking","60 Months","215 Months",{"count":55,"type":23},[89],"NA","Children with medical complexity (CMC) often have trouble breathing at night and need to use a breathing machine. This breathing machine is called noninvasive positive pressure ventilation (NiPPV). The use of NiPPV has been shown to improve quality of life and survival in children. Before it is used, NiPPV must first be tested to see what the correct 'machine settings' are for each child. This is usually done in the sleep laboratory at the hospital during a one-night stay. However, sleep studies in the hospital are disruptive and hard for CMC and their families because of the new environment and limited access to the equipment, supplies, comfort items and the routine their child has at home. Patients and families would prefer to start NiPPV at home but there needs to be more research on this to make sure it is possible and safe. This study will evaluate a new model of care to start NiPPV in the home. CMC aged 5-17 years old and starting NiPPV will be assigned at random, like a coin toss, to start NiPPV in the home or to start NiPPV in the sleep laboratory. The investigators will assess the feasibility and safety of the two ways to start NiPPV. This study will be the first step towards developing a study to evaluate if home NiPPV starts are effective. Starting NiPPV at home has the potential to improve the use of NiPPV (ie early adherence predicts long-term use) resulting in both medical benefits as well as improved quality of life for CMC and their families.",[92],"Sleep-Disordered Breathing",[94,95],"noninvasive ventilation","home mechanical ventilation","2026-05-03",{"date":98,"type":37},"2026-05-07",{"date":100,"type":37},"2023-06-21",{"date":74,"type":23},{"name":103,"class":77},"The Hospital for Sick Children",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":18,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":115,"studyType":116,"phases":4,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100538550","the-pars-study-paediatric-advanced-respiratory-service-study---an-observational-diagnostic-feasibility-study-100538550","NCT06292299","The PARS Study: Paediatric Advanced Respiratory Service Study - An Observational Diagnostic Feasibility Study","PARS","Inclusion Criteria:\n\nGroup 1 - CR-poly group\n\n* Patient undergoing overnight CR-poly\n* Age birth to \\>=16 years\n* Are willing and able to give informed assent\u002Fconsent or have available next of Kin to provide informed consent on the participant\\'s behalf\n* Able (in the Investigators opinion) to comply with all study requirements\n* Can speak and read English\n\nGroup 2 - Apnoea group\n\n* Inpatient in neonatal unit\n* Age birth (from 30 weeks gestational age) to term corrected\n* Parents willing and able to give informed consent\n* Able (in the Investigators opinion) to comply with all study requirements\n* Can speak and read English\n\nGroup 3- VT Group attending epilepsy monitoirng unit\n\n* Inpatient receiving video-telemetry epilepsy monitoring unit\n* Age birth to \\\u003C16 years\n* Parents willing and able to give informed consent\n* Able (in the Investigators opinion) and willing to comply with all study requirements\n* Can speak and read English\n\nExclusion Criteria:\n\nGroup 1 - CR-poly group\n\n* Unable to provide consent and no next of kin to provide consent on participants behalf\n* Treating clinician deems patient inappropriate to be included in study\n\nGroup 2 - Apnoea group\n\n* No next of kin to provide consent on participants behalf\n* Treating clinician deems patient inappropriate to be included in study\n\nGroup 3- VT Group attending epilepsy monitoirng unit\n\n* Unable to provide consent and no next of kin to provide consent on participants behalf\n* Treating clinician deems patient inappropriate to be included in study","1 Minute","16 Years",{"count":114,"type":23},225,"7 Days","OBSERVATIONAL","Diagnostic investigations in paediatric respiratory and sleep medicine are often challenging due to patient size (due to prematurity), tolerability, and compliance with \"gold standard equipment\". Children with sensory\u002Fbehavioural issues, at increased risk of sleep disordered breathing (SDB), often find tolerating standard diagnostic equipment difficult. There is a need to develop non-invasive, wireless, devices designed for the paediatric population. Devices must address health in-equalities as high-risk children, with low birth weights, genetic syndromes, or complex neuro-disabilities, are often unable to undergo current investigations, particularly in sleep medicine. Prompt and accurate diagnosis of SDB is important to facilitate early intervention and improve outcomes\n\nInfants in the neonatal period can have immature breathing control which manifests as excessive central breathing pauses, apnoea's, whilst asleep requiring oxygen therapy. There is also a risk to newborn term infants of sudden unexpected neonatal collapse, even in \"low risk\" babies. Diagnosis of breathing issues in babies can be challenging since babies are often too small for standard monitoring equipment. Effective monitoring and appropriate treatment of apnoea's has been shown to improve prognosis in terms of 5-year mortality and neurodevelopmental outcomes.\n\nChildren with epilepsy are at risk of epileptic apnoea during a seizure (ictal) or post-ictal apnoea following an epileptic seizure. Epileptic and post-ictal apnoea have been implicated as causes of sudden unexpected death in epilepsy (SUDEP). Epilepsy affects approx. 50 million people worldwide. The risk of SUDEP varies in different underlying causes of epilepsy but is estimated to be the cause of 1.2 deaths for every 1,000 children with epilepsy each year.\n\nThis observational study is part of a phased clinical program of research that aims to validate a small wearable biosensor developed by PneumoWave Ltd in a paediatric clinical setting with the overall primary endpoints of monitoring and assessing respiratory pattern as an aid to sleep diagnostics, and as a device to monitor apnoea in neonatal patients and children with epilepsy at risk of SUDEP.",[32,119,120,121],"Apnea of Prematurity","Respiratory Rate","Sudden Unexpected Death in Epilepsy",[32,123,124,125,120,126,127],"Neonatal Apnoea","Sleep Diagnostics","Wearable Device","Respiratory Pattern","Epilepsy","2026-04-13",{"date":130,"type":37},"2026-04-14",{"date":132,"type":37},"2024-03-01",{"date":134,"type":23},"2027-12",{"name":136,"class":77},"NHS Greater Clyde and Glasgow",2,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":24,"phases":147,"briefSummary":148,"conditions":149,"keywords":156,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":178,"leadSponsor":180,"locationsCount":45},"100628633","evolution-of-hypoxic-burden-and-sympatheticparasympathetic-balance-in-patients-with-pulmonary-hypertension-100628633","NCT07464184","Evolution of Hypoxic Burden and Sympathetic\u002FParasympathetic Balance in Patients With Pulmonary Hypertension","HRV&PH","Inclusion Criteria:\n\n* Patients over 18 years of age\n* With precapillary pulmonary hypertension confirmed by pulmonary artery catheterization\n* With an indication for pulmonary artery vasodilator treatment\n* Affiliation with a social security system\n* Women of childbearing age using effective\u002Fhighly effective contraception (see CTFG) (estrogen-progestogen or intrauterine device or tubal ligation) for 6 months and a negative urine pregnancy test at inclusion, for the duration of the study.\n* Postmenopausal women: confirmed diagnosis (non-medically induced amenorrhea for at least 12 months prior to the inclusion visit)\n* Individuals who have read and understood the information letter and signed the consent form\n\nNon-Inclusion Criteria:\n\n* Treatment with non-invasive ventilation\n* Eisenmenger syndrome\n* Systemic scleroderma\n* Neurodegenerative disease other than isolated peripheral neuropathies.\n* Untreated and\u002For uncontrolled cardiac rhythm or conduction disorders, including permanent AF\n* Untreated coronary artery disease or diagnosis of myocardial infarction within the last six months\n* Pacemaker wearer\n* Pregnant or breastfeeding women, or women who are not using reliable contraception\n* Persons deprived of their liberty by administrative or judicial decision or persons under judicial protection\u002Fguardianship or curatorship\n* History of psychological or sensory illness or abnormality that may prevent the subject from fully understanding the conditions required for participation in the protocol or prevent them from giving their informed consent",{"count":146,"type":23},60,[89],"Background and Rationale:\n\nSleep-disordered breathing and nocturnal hypoxemia are highly prevalent in patients with precapillary pulmonary hypertension (PH), and current guidelines recommend systematic sleep assessment in this population. In obstructive sleep apnea, nocturnal hypoxic burden-defined as the area under the SpO₂ desaturation curve associated with respiratory events (%.min\u002Fh)-has demonstrated strong prognostic value for cardiovascular morbidity and mortality. However, its role in precapillary PH has not yet been investigated. Evaluating hypoxic burden in this population may refine indications and therapeutic targets for nocturnal oxygen therapy.\n\nIn addition, pulmonary hypertension is characterized by autonomic nervous system (ANS) dysfunction, including increased sympathetic tone, reduced heart rate variability (HRV), and a higher incidence of cardiac arrhythmias, all associated with worse prognosis. The reduction in HRV is particularly deleterious when occurring during restorative slow-wave sleep (N3), a phase marked by predominant parasympathetic activity essential for cardiovascular recovery and homeostasis. A better understanding of the interaction between nocturnal hypoxemia and ANS modulation may provide new prognostic markers and potential therapeutic targets in PH.\n\nObjectives:\n\n1. To describe the evolution of nocturnal hypoxic burden over time in patients with precapillary pulmonary hypertension (at baseline, 12 months, and 24 months).\n2. To describe the longitudinal evolution of HRV parameters (RMSSD, LF\u002FHF ratio, HF) at baseline, 12 months, and 24 months.\n3. To evaluate cross-sectional correlations (at baseline, M12, and M24) between HRV parameters, hypoxic burden, oxygen desaturation, apnea-hypopnea index (AHI), and clinical status.\n4. To evaluate longitudinal correlations between changes in HRV parameters, hypoxic burden, desaturation, AHI, and clinical status between baseline and M12, and between baseline and M24.\n5. To assess the 2-year prognostic value of HRV parameters and hypoxic burden for adverse clinical outcomes.\n\nStudy Design and Population:\n\nThis is a prospective, single-center observational cohort study conducted at the Pulmonary Hypertension Referral Center of Rouen University Hospital. The cohort design allows longitudinal assessment of HRV, hypoxic burden, and clinical status, enabling both cross-sectional and longitudinal correlation analyses, as well as prognostic evaluation. A total of 60 adult patients (≥18 years) with precapillary pulmonary hypertension confirmed by right heart catheterization and requiring pulmonary arterial vasodilator therapy will be included.\n\nParticipants will undergo full overnight polysomnography (PSG) at:\n\n* Baseline (inclusion)\n* 12 months (M12)\n* 24 months (M24) For incident cases, baseline PSG will be performed prior to initiation of vasodilator therapy. All patients will continue to receive standard-of-care management according to current European guidelines for pulmonary hypertension.\n\nDescriptive analyses and cross-sectional correlations will pool repeated measures (excluding incident baseline values for generalization to prevalent cases). Intra-subject correlation will be accounted for using bootstrap methods. Longitudinal analyses will assess changes over time and prognostic associations. The prognostic value of HRV and hypoxic burden will be evaluated over a 2-year follow-up period. This study explores an original dimension of precapillary pulmonary hypertension pathophysiology by investigating the interaction between nocturnal oxygenation, autonomic dysfunction, and clinical evolution. Identification of hypoxic burden and HRV as prognostic markers may contribute to improved risk astratification and therapeutic optimization in this high-risk population.",[150,151,60,152,153,154,155],"Precapillary Pulmonary Hypertension","Pulmonary Arterial Hypertension","Nocturnal Hypoxemia","Autonomic Nervous System Dysfunction","Heart Rate Variability (HRV)","Cardiovascular Risk",[157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173],"Precapillary pulmonary hypertension","Pulmonary arterial hypertension","Hypoxic burden","Nocturnal hypoxia","Polysomnography","Sleep-disordered breathing","Heart rate variability (HRV)","RMSSD","LF\u002FHF ratio","High frequency","Autonomic nervous system","Sympathetic activation","Parasympathetic tone","Risk stratification","Prognostic markers","Right heart failure","Apnea-Hypopnea Index (AHI)","2026-04-10",{"date":176,"type":37},"2026-04-15",{"date":72,"type":23},{"date":179,"type":23},"2030-01-01",{"name":181,"class":77},"University Hospital, Rouen",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":18,"minAge":188,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":192,"conditions":193,"keywords":197,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":212},"100489687","evaluating-the-genetics-and-immunology-of-periodic-fever-aphthous-stomatitis-pharyngitis-and-cervical-adenitis-pfapa-syndrome-and-other-tonsil-disorders-100489687","NCT05656365","Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders","* INCLUSION CRITERIA:\n\nParticipants must meet all the following inclusion criteria to be eligible for this study:\n\n1. Aged \\>=1 month. To be seen at the NIH CC, participants must be \\>=3 years of age.\n2. Diagnosed with PFAPA or another tonsil disorder, or has symptoms consistent with these conditions, as determined by the investigator.\n3. Able to provide informed consent (for ages \\>=18 years) or has a parent or guardian who can provide informed consent on their behalf (for ages \\\u003C18 years).\n4. Willing to allow specimens and data to be stored for future research.\n5. Willing to allow genetic testing on their biospecimens.\n\nEXCLUSION CRITERIA:\n\nAn individual who has any condition that, in the judgment of the investigator, may put them at undue risk or make them unsuitable for participation in the study will be excluded.","1 Month","99 Years",{"count":191,"type":23},1500,"Background:\n\nPeriodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) is the most common periodic fever syndrome of childhood. Symptoms can include swelling of the glands in the throat, mouth ulcers, and tonsillitis. Removal of the tonsils can stop the periodic flareups. But researchers do not know how PFAPA develops. In this natural history study, researchers will collect specimens and data from people with PFAPA to see what they might have in common.\n\nObjective:\n\nTo collect blood and other specimens from people with PFAPA to learn more about the illness.\n\nEligibility:\n\nPeople aged 1 month or older with symptoms of PFAPA or another tonsil disorder.\n\nDesign:\n\nParticipants will be screened. Their medical records will be reviewed. Researchers will ask about a family history of PFAPA.\n\nThe following specimens may be collected:\n\nBlood. Blood will be drawn either from a needle inserted into a vein or from a prick in the finger or heel.\n\nMucus and cells. A stick with soft padding on the tip may be rubbed inside the nostrils or mouth.\n\nStool.\n\nSaliva.\n\nTissue samples may be taken if participants are having surgery to remove the tonsils or adenoids. Participants having surgery may also have a nasopharyngeal wash; salt water will be squirted into the back of the throat and then sucked back out with a syringe.\n\nMost participants will provide specimens only once. They can do this in person at the clinic; they can also have their local health providers send specimens to the researchers. Some participants may have optional follow-up visits over 10 years.",[194,59,195,196,32],"Periodic Fever, Aphthous Stomatitis, Pharyngitis, And Cervical Adenitis (Pfapa)","Tonsillitis","Tonsil Disorder",[198,199,200,195,59,32,201],"Genome-Wide Association Study (Gwas)","Immunology","Autoinflammation","Natural History","2026-04-07",{"date":204,"type":37},"2026-04-08",{"date":206,"type":37},"2023-05-23",{"date":208,"type":23},"2038-12-31",{"name":210,"class":211},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",3,{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":24,"phases":223,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":45},"100371592","phase-4-central-sleep-apnea--physiologic-mechanisms-to-inform-treatment-100371592","NCT04118387","Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment","Central Sleep Apnea: Physiologic Mechanisms to Inform Treatment","CSA","Inclusion Criteria:\n\n* Men and women Veterans with central sleep apnea, defined as Apnea Hypopnea Index (AHI)\\>15\u002Fhour with CAHI\\>5\u002Fhour, will be included in the experiments\n\nExclusion Criteria:\n\n* less than 18 years old\n* pregnant or breastfeeding female\n* have severe respiratory disease that require to be on oxygen\n* recent health event that may affect the ability to participate in the study,\n* Body Mass Index (BMI) is \\>40 kg\u002Fm2\n* significant insomnia\n* mental instability\n* recent health event that may affect sleep\n* if at any time the principal investigator (PI) identifies that a certain drug is not suitable, or are unable to use the device that is used to treat sleep apnea, will be not be allowed to participate in the study",{"count":222,"type":23},200,[224],"PHASE4","Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.",[32,227],"Able Bodied",[229,230,231,232,233,234,235,236,237,238,239],"Central sleep apnea","Polysomnography (PSG)","Respiratory arousal threshold","Apnea Hypopnea index","Central Apnea Hypopnea Index","Breathing instability","Apneic Threshold (AT)","Peripheral chemoreflex sensitivity","CO2 reserve","Plant gain","Controller gain","2026-03-11",{"date":242,"type":37},"2026-03-13",{"date":244,"type":37},"2021-01-07",{"date":246,"type":23},"2026-12-31",{"name":43,"class":44},{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":18,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":24,"phases":259,"briefSummary":260,"conditions":261,"keywords":267,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":281},"100483466","lateral-pharyngoplasty-outcomes-in-children-undergoing-tonsillectomy-100483466","NCT05575401","Lateral Pharyngoplasty Outcomes in Children Undergoing Tonsillectomy","Post-operative Outcomes of Tonsillectomy With Lateral Pharyngoplasty Versus Tonsillectomy Alone in Children: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants ages 3-17 years of age undergoing tonsillectomy +\u002F- adenoidectomy at Loma Linda University Health\n\nExclusion Criteria:\n\n* Subjects with congenital syndromes and\u002For developmental delay\n* Subjects with cancer\n* Subjects with gastrostomy tube use or dependence\n* Subjects undergoing intracapsular tonsillectomy","3 Years","17 Years",{"count":258,"type":23},160,[89],"The goal of this treatment study is to determine if doing lateral pharyngoplasty with tonsillectomy is better for children than doing tonsillectomy alone. The main questions it aims to answer are:\n\n* Do children experience less pain after surgery when lateral pharyngoplasty is performed with tonsillectomy compared to tonsillectomy alone?\n* Do children eat\u002Fdrink better when lateral pharyngoplasty is performed with tonsillectomy compared to tonsillectomy alone?\n* Is there a lower risk of bleeding after tonsillectomy when lateral pharyngoplasty is performed? Researchers will compare children undergoing tonsillectomy and lateral pharyngoplasty with children undergoing tonsillectomy alone to see if the participants experience less pain, better oral intake, and less bleeding complications after surgery. Parents of participants will be asked to record pain scores and pain medications given, approximate amounts of daily oral intake, and any complications after surgery.",[92,262,263,195,264,265,266],"Sleep Apnea Syndromes in Children","Sleep Apnea, Obstructive","Tonsillar Hypertrophy","Tonsil Stone","Tonsil Disease",[268,269,270,271],"Tonsillectomy","Post-tonsillectomy hemorrhage","Post-tonsillectomy complication","Lateral pharyngoplasty","2026-02-19",{"date":274,"type":37},"2026-02-23",{"date":276,"type":37},"2023-05-17",{"date":278,"type":23},"2026-12",{"name":280,"class":77},"Loma Linda University",4,{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":24,"phases":290,"briefSummary":225,"conditions":291,"keywords":292,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":45},"100609134","phase-4-central-apnea-in-heart-failure-physiological-mechanisms-to-inform-treatment-100609134","NCT07210606","Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment","CSA-HF","Inclusion Criteria:\n\n* Men and Women Veterans with central sleep apnea, defined as Apnea Hypopnea Index (AHI)\\>15\u002Fhour with CAHI\\>5\u002Fhour, will be included with the experiments.\n* Those with chronic, stable heart failure with reduced ejection fraction, receiving stable optimized guideline-based therapy and no hospitalizations or change in the medical regimen for the past 90 days before enrollment.\n\nExclusion Criteria:\n\n* less than 18 years old\n* pregnant or breastfeeding females\n* moderate or severe obstructive or restrictive lung disease, including supplemental o2 use\n* current treatment for CSA, including any form of PAP in the past three months, or phrenic nerve situation.\n* too ill to engage in the study procedures, inability to provide consent for participation.\n* a history of cardiac arrhythmia\n* Alcohol or substance abuse (less than 90 days sobriety) or current participation in a treatment program\n* depression or a history of suicidality\n* severe insomnia (ISI\\>21) or reported short sleep duration (\\\u003C6 hours)\n* PAP-emergent central sleep apnea\n* Lack of PAP acceptance\u002Fadherence after a one-week home PAP trial after enrollment.\n\nAdditional Trazodone Exclusions:\n\n* Prolonged QT on baseline ECG, using medications that inhibit CYP3A4\n* Patients with severe renal impairment (GFR \\\u003C 20ml\u002Fmin\u002F1.73m2) or end-stage renal disease",{"count":222,"type":23},[224],[32,227],[293,230,294,295,233,296,235,297,237,238,239,298,299,300,301],"Central Sleep Apnea","Respiratory Arousal Threshold","Apnea Hypopnea Index","Breathing Instability","Peripheral Chemoreflex Sensitivity","Cheyne Stokes Breathing (CSB)","Carotid Body Function","Peripheral Chemoresponsiveness","Heart Failure","2026-01-06",{"date":304,"type":37},"2026-01-07",{"date":306,"type":23},"2026-10-01",{"date":308,"type":23},"2030-12-31",{"name":43,"class":44},{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":17,"sex":18,"minAge":255,"maxAge":256,"enrollmentInfo":318,"targetDuration":4,"studyType":24,"phases":320,"briefSummary":321,"conditions":322,"keywords":325,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":45},"100560414","phase-4-optimization-of-pediatric-tonsillectomy-to-improve-analgesia-100560414","NCT06576830","Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia","Single-Dose Intraoperative Methadone for Pain Management in Pediatric Tonsillectomy: A Randomized Double Blind Clinical Trial","OPTIMAL","Inclusion Criteria:\n\n1. Age \\>= 3 and \\\u003C 18 years\n2. Elective tonsillectomy +\u002F- adenoidectomy\n3. Signed informed consent by parent or legal guardian\n4. Children \\>= 12 years must provide signed written consent, Children \\>= 7 years must provide verbal assent\n5. Negative pregnancy test within 48 hours for post pubescent females\n\nExclusion Criteria:\n\n1. History of chronic kidney or liver disease\n2. Current diagnosis of a chronic pain disorder\n3. Planned admission to the Pediatric Intensive Care Unit (PICU)\n4. Additional procedures under general anesthesia for which opioids would be prescribed",{"count":319,"type":23},440,[224],"The purpose of this study is to compare the use of short acting opioids (fentanyl\u002Fhydromorphone) with long acting opioids (methadone) for pain control following tonsillectomy surgery in children and adolescents.",[323,264,195,324,92],"Pain, Postoperative","Pediatric Sleep Apnea",[326,268,327],"Methadone","Opioid","2025-12-01",{"date":330,"type":37},"2025-12-05",{"date":332,"type":37},"2024-11-21",{"date":334,"type":23},"2029-06-01",{"name":336,"class":77},"Duke University",{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":357,"locationsCount":45},"100606414","exploring-the-patterns-of-sleep-disordered-breathing-in-systemic-sclerosis-patients-100606414","NCT07175246","Exploring the Patterns of Sleep Disordered Breathing in Systemic Sclerosis Patients","Inclusion Criteria:\n\nAge ≥ 18 years, with Confirmed diagnosed of SSc (2013 ACR\u002FEULAR criteria).\n\nExclusion Criteria:\n\n* Pre-existing primary sleep disorders diagnosed before SSc diagnosis\n* Use of sedatives or hypnotics within the last month that significantly alter sleep architecture\n* Severe psychiatric or neurological conditions\n* Refusal to participate in the study",{"count":344,"type":23},30,"Systemic sclerosis (SSc) is a chronic autoimmune connective tissue disease characterized by progressive fibrosis of the skin and internal organs. Fatigue, non-restorative sleep, and poor sleep quality are frequently reported among patients with SSc, yet these symptoms remain under-recognized and under-investigated in clinical practice. Despite growing awareness of the burden of sleep-related symptoms, there is a significant lack of objective data regarding sleep disturbances in this population, particularly those assessed using polysomnography (PSG).",[347,92],"Systemic Sclerosis",[349,30,350],"systemic sclerosis","Insomnia","2025-09-12",{"date":353,"type":37},"2025-09-16",{"date":355,"type":23},"2025-09-20",{"date":306,"type":23},{"name":358,"class":77},"Assiut University",{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":17,"sex":367,"minAge":19,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":45},"100509066","sleep-disordered-breathing-endothelial-function-and-adverse-events-in-pregnancy-100509066","NCT05908591","Sleep Disordered Breathing, Endothelial Function, and Adverse Events in Pregnancy","SLEEP: Sleep Disordered Breathing, Endothelial Function, and Adverse Events in Pregnancy","SLEEP","Inclusion Criteria:\n\n* over 18 years of age\n* pregnant (20-24 weeks gestation at enrollment)\n\nExclusion Criteria:\n\n* worked shift work past 11pm in the previous month\n* previously diagnosed with a sleep disorder by a physician","FEMALE",{"count":369,"type":23},109,"This is a prospective longitudinal cohort study whereby pregnant individuals are asked to complete an 8-day testing protocol to measure their sleep and cardiovascular health at two timepoints during pregnancy.",[372,92],"Pregnancy Related",[374],"Cardiovascular Health","2025-05-05",{"date":377,"type":37},"2025-05-07",{"date":379,"type":37},"2023-01-01",{"date":381,"type":23},"2027-04-18",{"name":383,"class":77},"University of Alberta",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":392,"enrollmentInfo":393,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":395,"conditions":396,"keywords":401,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":45},"100393144","apnea-stroke-and-incident-cardiovascular-events-100393144","NCT04399200","Apnea, Stroke and Incident Cardiovascular Events","Sleep Apnea Syndrome and Incidence of Major Adverse Cardiac and Cerebrovascular Events (MACCEs) After a First Stroke","ASCENT","Inclusion Criteria:\n\n* Male or female, aged 18 to 85 years\n* Admitted in the stroke unit no later than 72h after the onset of stroke symptoms:\n\n  * First stroke confirmed by computed tomography scan or magnetic resonance imaging, whatever the localization\n  * Initial or recurrent TIA, as defined by a brief and sudden neurological dysfunction for which an ischemic cause is presumed, with symptoms lasting less than 24 hours, and\u002For with no visible lesion on neuroimaging evaluation.\n* Score on the Modified Ranking scale (mRS) ≤1 before stroke\n* Signed informed consent by patient or his\u002Fher relative if not able\n* Patient eligible to carotid endarterectomy (for ancillary study only)\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Past history of stroke\n* Inability to follow rehabilitation procedure\n* Patients with ongoing treatment for SDB\n* Exclusion period for another study\n* Patients not affiliated to a French social and health insurance system or equivalent\n* Prisoners or patients who require protection by the law","85 Years",{"count":394,"type":23},1620,"This prospective cohort study aims to compare the proportion of cardiac or cerebrovascular events after a first stroke, a first transient ischemic attack (TIA) or recurrent TIA, between sleep-disordered breathing (SDB) and non-SDB (control) patients, one year after SDB diagnosis, performed 3 months after stroke onset.\n\nThe primary outcome is a composite endpoint composed of cardiac or cerebrovascular events regrouping: death from any cardiac or cerebrovascular cause, non-fatal stroke, and non-fatal acute coronary disease.\n\n1620 patients, in the acute phase of a first stroke, TIA or recurrent TIA will be included in the cohort.\n\nClinical, neuroimaging, sensorimotor, cognitive and biological parameters will be collected at inclusion. Three months after stroke or TIA onset, polysomnography will be performed for SDB diagnosis. Patients will be considered as having SDB for an Apnea-Hypopnea Index (AHI) \\> 15 events\u002Fhour, or to the control group otherwise. The same clinical, imaging, cognitive and biological assessments than during the first visit will be performed; incident (new) cardiovascular events will be collected. Three months later, and at 1, 2, 3, 4 and 5 years after SDB diagnosis, the same clinical, cognitive, sensorimotor, and sleep-related evaluations will be performed. In addition to the aforementioned parameters, incident cardiovascular outcomes will be collected, at the same time points. The primary study outcome will be retrieved one year after stroke onset.",[397,60,398,263,399,400],"Stroke","Sleep Apnea Syndromes","Sleep Apnea, Central","Fragmentation, Sleep",[397,60,402,403],"Cardio-Vascular Events","Atherosclerosis","2025-02-07",{"date":406,"type":37},"2025-02-11",{"date":408,"type":37},"2020-07-13",{"date":410,"type":23},"2035-06-01",{"name":412,"class":77},"University Hospital, Grenoble",{"id":414,"slug":415,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":18,"minAge":419,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":423,"conditions":424,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":45},"100465145","post-vent-the-sequelae-personalized-prognostic-modeling-for-consequences-of-neonatal-intermittent-hypoxemia-in-preterm-infants-at-pre-school-age-100465145","NCT05336890","Post-Vent, the Sequelae: Personalized Prognostic Modeling for Consequences of Neonatal Intermittent Hypoxemia in Preterm Infants at Pre-School Age","Inclusion Criteria:\n\n* Enrolled in any Institutional Review Board (IRB) protocol of the Pre-Vent Study that had signed consent, or in any IRB protocol of the Pre-Vent Study that authorized re-contact for future research\n* Born \\\u003C29 weeks gestational age\n* Age at enrollment less than 7 years old\n\nExclusion Criteria:\n\n* Subject was withdrawn from the Pre-Vent study after signing Pre-Vent consent form, for any reason\n* Subject had no physiological data recorded as part of Pre-Vent\n* Lack of regulatory approval from local IRB or Department of Children and Family Services (DCFS) to recontact subjects\n* Adopted by non-consenting family\n* Parent refused further contact, prior to approach for Post-Vent\n* Infant enrolled in Pre-Vent at Washington University St Louis, which is not a Post-Vent participating site.","30 Weeks","83 Months",{"count":422,"type":23},500,"Despite improved survival of extremely premature infants in recent decades, neonatal intensive care unit (NICU) graduates are diagnosed with asthma, sleep disordered breathing (SDB) in childhood, and neurodevelopmental impairments (NDI) at significant rates, disproportionate to their term peers. Early detection and intervention are critical to mitigate the impact of these impairments. Mechanisms leading from premature birth to these undesirable outcomes remain unclear, and accurate prognostic measures are lacking.\n\nThis study wants to learn if these problems are related to certain patterns of breathing that babies had while they were in the NICU.",[425,426,92,427],"Premature Birth","Asthma in Children","Neurodevelopmental Disorders","2024-12-03",{"date":430,"type":37},"2024-12-05",{"date":432,"type":37},"2022-11-01",{"date":434,"type":23},"2026-06-30",{"name":436,"class":77},"Ann & Robert H Lurie Children's Hospital of Chicago",{"id":438,"slug":439,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":11,"sex":18,"minAge":444,"maxAge":445,"enrollmentInfo":446,"targetDuration":4,"studyType":24,"phases":447,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":458,"locationsCount":45},"100564829","comparison-of-two-reeducation-methods-in-children-with-persistent-sleep-apnea-a-randomized-controlled-trial-100564829","NCT06634264","Comparison of Two Reeducation Methods in Children With Persistent Sleep Apnea, a Randomized Controlled Trial","PERSIST-B-RCT","Inclusion Criteria:\n\nparticipants must:\n\n* present signs of obstructive sleep apnea: snoring, apnea \u002F respiratory pauses audible by the entourage (objectivized by a score, to the Pediatric Sleep Questionnaire (PSQ) , greater than or equal to 0.33- This questionnaire comprises twenty-two Questions and has a good sensitivity (83%) and specificity (87%) in screening for pediatric sleep apnea.\n* be programmed for adenoidectomy, tonsillectomy or adeno-tonsillectomy within 3 months (or more).\n\nExclusion Criteria:\n\nparticipants should not:\n\n* present with a craniofacial syndrome nor a severe medical condition with complex medical management,\n* present with an abnormality of the neuromuscular tone (such as Duchenne myopathy or cerebral palsy)\n* receive orthodontic therapy during the study\n* have a class III malocclusion (mandibular prognathy type), for which a propulsion oral appliance is contraindicated because it may aggravate mandibular prominence. Maxillary deficiency is not a exclusion criterion.\n* A non-nutritive oral habit such as digital sucking (or pacifier) that persists because it interferes with oral reeducation and is a contraindication to orthodontic treatments. Children who have recently stopped such a habit may be included in the study.","4 Years","14 Years",{"count":146,"type":23},[89],"Myofunctional therapy has been shown to be effectively reduce symptoms of paediatric obstructive sleep apnea, usually performed after adenotonsillectomy.\n\nThis study aims to evaluate the effectiveness of Passive Oral Myofunctional Reeducation (using a flexible oral appliance) compared to nasal hygiene alone (control group), in a population of children scheduled for adenotonsillectomy.",[450,92,451],"Obstructive Sleep Apnea of Child","Adenotonsillar Hypertrophy","2024-10-07",{"date":454,"type":37},"2024-10-09",{"date":456,"type":37},"2024-03-20",{"date":41,"type":23},{"name":459,"class":77},"Université de Montréal",{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":4,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":116,"phases":4,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":45},"100296671","sleep-disordered-breathing-after-solid-organ-transplantation-100296671","NCT03142022","Sleep-disordered Breathing After Solid Organ Transplantation","Inclusion Criteria:\n\n* Patients 1 year after lung transplantation\n\nExclusion Criteria:\n\n* Refusal of PSG\n* Medical contra-indication to perform PSG",{"count":467,"type":23},300,"Sleep-disordered breathing (SDB) describes a group of disorders in which partial or complete cessation of breathing occurs many times throughout the night, resulting in daytime sleepiness or fatigue that interferes with a person's ability to function and reduces quality of life. Transplantation has become an important treatment modality for end-stage organ failure. Transplant recipients are now living longer and, hence, develop chronic adverse medical conditions. Furthermore, transplantation is associated with weight gain. Despite the high prevalence of poor sleep and cardiovascular conditions among transplant patients, SDB is not well studied in these patients.",[470,60],"Lung Transplantation","2024-07-02",{"date":473,"type":37},"2024-07-03",{"date":475,"type":4},"2014-11",{"date":477,"type":23},"2025-12",{"name":479,"class":77},"Universitaire Ziekenhuizen KU Leuven"]